The trial’s primary endpoint is pCR, with secondary endpoints including event-free survival (EFS), overall survival, safety, ...

AstraZeneca (AZN) and Daiichi Sankyo (DSNKY) announce that Enhertu hit the main goal in a Phase 3 trial for early-stage ...

Less than three weeks after AstraZeneca and Daiichi Sankyo reported positive results for oncology powerhouse Enhertu in a ...

UK-based pharma major AstraZeneca and its Japanese partner Daiichi Sankyo are moving to expand the reach of their blockbuster ...

AstraZeneca (AZ) and Daiichi Sankyo have shared positive results from a late-stage study of their HER2-directed antibody drug ...

Drugmaker AstraZeneca revealed on Wednesday that it had received "positive high-level results" from a Phase III trial on its ...

AstraZeneca and Daiichi Sankyo's anti-HER2 drug Enhertu has been shown to provide a benefit in a phase 3 trial in early-stage ...

AstraZeneca (LSE:AZN) recently experienced positive developments, including the European approval of Calquence for mantle ...

Clinical Trials Arena · Jo Panuwat D/Shutterstock. AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan), followed by paclitaxel, trastuzumab and pertuzumab (THP), has shown ...

Topline results from the Phase III DESTINY-Breast11 trial show that Enhertu (trastuzumab deruxtecan) followed by paclitaxel, ...

AstraZeneca and Daiichi Sankyo’s Enhertu followed by THP showed an improved safety profile vs. standard of careFirst Phase III trial to demonstrate benefit of Enhertu in early breast cancer Positive ...

Treatment with an Enhertu regimen significantly improved pathologic complete responses for patients with high-risk ...